SAB Biotherapeutics is holding its 2026 virtual annual stockholder meeting on June 18, 2026 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/SABS2026. Stockholders will vote on electing four Class II directors for three-year terms and ratifying EisnerAmper LLP as independent auditor for 2026.
Holders of 50,951,037 shares of common stock of record on April 20, 2026 may vote online, by phone, mail or during the virtual meeting. The board describes its governance structure, committee membership, director independence, director compensation and major stockholders, and recommends voting “FOR” all director nominees and “FOR” auditor ratification.
SAB Biotherapeutics reported new Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established type 1 diabetes. In the six-person cohort, four participants received SAB-142 and two received placebo.
All four treated participants preserved C-peptide, with three classified as super responders showing increases above baseline through Day 120, while the placebo patient showed a decline consistent with disease progression. Treated participants’ continuous glucose monitoring time in range improved from 73% at baseline to 85% at Day 120 without higher exogenous insulin use.
Biomarker data indicated CD4+ T conventional cell exhaustion without immunodepletion, supporting SAB-142’s intended mechanism. A registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 type 1 diabetes is ongoing, with topline data expected in the second half of 2027.
SAB Biotherapeutics, Inc. chief medical officer Alexandra Kropotova reported a routine tax-related share withholding. On the vesting of restricted stock units, 988 shares of common stock were withheld to satisfy tax obligations, rather than sold in the market. After this disposition, she holds 43,296 shares directly, including 8,743 unvested RSUs, each representing a right to receive one share of common stock.
RA Capital Management and affiliates report beneficial ownership of 7,311,225 shares of SAB Biotherapeutics common stock, representing 9.9% of the class. The position includes common shares, Series B preferred stock, preferred stock warrants and pre-funded warrants, all subject to ownership limits.
On March 19, 2026, the RA Capital Healthcare Fund purchased pre-funded warrants to acquire 2,753,246 common shares at $3.8499 per warrant share, for an aggregate purchase price of $10,599,721.78 funded from its working capital. These pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire, but contain a 9.99% beneficial ownership blocker.
SAB Biotherapeutics is offering shares of common stock and pre-funded warrants in a shelf-based public offering. The prospectus supplement describes an offering of common stock and, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share. The company’s common stock trades on The Nasdaq Capital Market under the symbol SABS, and it reported 47,609,899 shares outstanding as of December 31, 2025. The prospectus references proceeds, underwriting arrangements, a 30-day option for additional shares, and customary underwriting terms; specific offering amounts and pricing are presented only in completed prospectus pages. The supplement also summarizes business and clinical developments: SAB-142 is the lead clinical candidate, the company received an IND clearance in May 2024, announced positive Phase 1 topline data across multiple dates including additional Phase 1 data on March 10, 2026, and is advancing SAB-142 into a Phase 2b SAFEGUARD study after a Type B meeting with the FDA on May 29, 2025.
SAB Biotherapeutics (SAB BIO) reported additional Phase 1 data for its lead Type 1 diabetes therapy SAB-142. In a small cohort of six adults with established Stage 3 T1D, four participants receiving SAB-142 at 2.5 mg/kg showed preserved or increased C-peptide levels at Day 120, while the single placebo completer showed a decline consistent with expected disease progression.
The company highlights biomarker evidence of T‑cell exhaustion supporting the drug’s intended mechanism and notes a previously established Phase 1 safety profile without serum sickness and with transient, reversible lymphopenia. These results supported advancing SAB-142 into the global registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients, with topline data planned for the second half of 2027.
SAB Biotherapeutics is a clinical-stage company developing fully human, multi-specific immunoglobulin therapies, led by SAB-142 for autoimmune type 1 diabetes. SAB-142 advanced from positive Phase 1 results into a registrational Phase 2b SAFEGUARD trial in adults, adolescents and children with new-onset Stage 3 T1D.
For 2025, revenue fell to $0 from $1.3 million in 2024 following termination of a government contract, while research and development expenses rose to $34.4 million and general and administrative expenses increased to $14.6 million as the company expanded clinical and platform work.
SAB reported net income of $13.3 million in 2025 versus a $34.1 million net loss in 2024, driven mainly by a $62.8 million non-cash gain from changes in fair value of warrant liabilities and a $61.0 million total non-operating income line.
Liquidity strengthened significantly: cash, cash equivalents and investments reached $143.5 million at year-end 2025, supported by approximately $175 million of gross proceeds from a Series B preferred stock and warrant offering, and a new Form S-3 shelf for up to $300 million, including a $75 million at-the-market program with UBS.
Biotechnology Value Fund–affiliated investors reported a significant ownership position in SAB Biotherapeutics, Inc. As of the close of business on December 31, 2025, their funds and a managed account held 30,000 Tranche C warrants for Series A-3 Preferred Stock, convertible into 4,761,906 common shares.
The preferred shares convert at $6.30 per common share, based on a $1,000 per preferred share value, and the warrants are exercisable beginning November 23, 2023 for five years. Using 47,606,851 common shares outstanding as of November 10, 2025, the filing states BVF-related entities may be deemed to beneficially own up to approximately 9.1% of the class.
The structure includes a 9.99% “Maximum Percentage” cap that limits conversions so no holder, together with its affiliates and attribution parties, crosses that ownership threshold.
RTW Investments, LP and Roderick Wong, M.D. report their ownership in SAB Biotherapeutics, Inc. on an amended Schedule 13G. They beneficially own 1,587,302 shares of common stock, equal to 3.2% of the company.
The position reflects warrants held by RTW-managed funds to purchase Series A-3 Preferred Stock that is convertible into 1,587,302 common shares. RTW Investments and Dr. Wong share voting and dispositive power over these shares, which are held by the RTW funds. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of SAB Biotherapeutics.
SAB Biotherapeutics, Inc. is the subject of a Schedule 13G showing that Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman collectively report beneficial ownership of 3,471,861 shares of SAB’s common stock, representing 7.3% of the class.
The Master Fund directly holds the 3,471,861 shares, and the ownership percentage is based on 47,606,851 outstanding shares as of November 10, 2025, as disclosed in SAB’s Form 10-Q. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, share voting and dispositive power over these shares. The filers certify the position was not acquired to change or influence control of SAB Biotherapeutics.